REFRACTORY NON-HODGKIN LYMPHOMA

This study tested a drug called palbociclib in 23 children and young adults (ages 1 to 21) whose cancers had come back or did not respond to standard treatment. The drug works by blocking certain proteins that help cancer cells grow. The goal was to see if the drug could shrink t…

This early-phase trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…

This study tested the drug nivolumab in 20 people with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal was to see ho…

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…

This study tested whether adding anakinra (a drug used for arthritis) to standard CAR-T cell therapy could prevent serious brain and nerve side effects in people with hard-to-treat non-Hodgkin lymphoma. Fifteen participants received both treatments. The goal was to see if the com…

This study tested a drug called samotolisib in 18 children and teens whose cancers (solid tumors, lymphoma, or related disorders) had spread, returned, or stopped responding to treatment. Only those with specific gene mutations (TSC or PI3K/MTOR) were eligible. The goal was to se…

This study tested a combination of pembrolizumab (an immunotherapy drug) and targeted radiation in 17 patients with non-Hodgkin lymphoma that had returned or stopped responding to treatment. The goal was to see if adding radiation could help the immune system fight the cancer bet…